Porokeratosis Punctata Palmaris Et Plantaris

Last update 01 Nov 2024

Basic Info

Synonyms

KERATODERMA, PALMOPLANTAR, PUNCTATE TYPE II, Keratoderma, Palmoplantar, Punctate Type Ii, PALMOPLANTAR KERATODERMA, PUNCTATE TYPE II

+ [10]

Introduction

A type of isolated punctate hereditary palmoplantar keratoderma with characteristics of multiple asymptomatic 1 to 2 mm-long, firm, hyperkeratotic projections (spiny keratosis) on the palms, soles and digits (typically confined to their volar and/or lateral aspects). Histopathologically compact columnar parakeratosis over hypo or agranular epidermis is observed.

100 Clinical Results associated with Porokeratosis Punctata Palmaris Et Plantaris

100 Translational Medicine associated with Porokeratosis Punctata Palmaris Et Plantaris

0 Patents (Medical) associated with Porokeratosis Punctata Palmaris Et Plantaris

Literatures (Medical) associated with Porokeratosis Punctata Palmaris Et Plantaris

01 Dec 2024·The Journal of dermatological treatment

Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis.

Article

Author: Papara, Cristian ; Hawro, Tomasz ; De Luca, David A ; Thaçi, Diamant ; Ständer, Sascha

INTRODUCTIONPalmoplantar pustular psoriasis (PPPP) is a chronic inflammatory skin disorder characterized by sterile pustules on the palms and soles, significantly impacting patients' quality of life. The pathogenesis of PPPP involves intricate interactions between immune dysregulation, environmental triggers, and genetic predisposition. The treatment of PPPP is challenging, and there is a need for effective and safe treatment options for patients.OBJECTIVEWe evaluated the efficacy and safety of deucravacitinib, a novel oral selective allosteric inhibitor of tyrosine kinase 2 (TYK2), in treating refractory PPPP.MATERIAL AND METHODSA retrospective analysis was conducted on five patients treated with deucravacitinib 6 mg/day, with clinical assessments at weeks 0, 4, and 16.RESULTSWhile initial worsening was observed in most patients, three showed improvement by week 16. One patient improved with the addition of methotrexate. Treatment was discontinued in two patients after week 16. Adverse effects were primarily viral and bacterial infections, and no serious adverse events occurred.CONCLUSIONCurrent therapeutic options for PPPP are limited, necessitating exploration of novel treatments. Deucravacitinib's mechanism of action, targeting TYK2, could show promise in PPPP management. However, its efficacy and safety in this specific condition require further investigation through larger, randomized controlled trials.

01 Jan 2023·International Journal of DermatologyQ4 · MEDICINE

Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review

Q4 · MEDICINE

Review

Author: Yeung, Jensen ; Zaaroura, Hiba ; Lytvyn, Yuliya ; Kim, Patrick ; Sachdeva, Muskaan ; Mufti, Asfandyar ; Abduelmula, Abrahim ; Lu, Justin D. ; Kwan, Sarah

AbstractBackgroundPalmoplantar pustulosis (PPP) and palmoplantar pustular psoriasis (PPPP) are chronic inflammatory skin conditions characterized by eruptions of sterile pustules on the palms and/or soles. Biologic use has been associated with PPP and PPPP development in the literature.ObjectivesTo identify PPP and PPPP associated with biologics and summarize reported treatments and outcomes.MethodsWe systematically searched in MEDLINE and Embase for articles that reported PPP or PPPP during biologic treatment. After a full‐text review, 53 studies were included for analysis.ResultsWe identified 155 patients with PPP/PPPP onset during biologic treatment, with a mean age of 44.1 years and a female preponderance (71.6%). The most frequently reported biologics were adalimumab (43.9%) and infliximab (33.3%). IL‐17 inhibitors, secukinumab (7.6%) and brodalumab (1.5%), were reported only in association with PPPP. Overall, 58.8% of patients had complete remission (CR) in 3.6 months and 23.5% had partial remission (PR) in 3.7 months. The most common treatments that led to CR were topical corticosteroids (n = 16) and biologic switching (n = 8).ConclusionsClinicians should anticipate PPP or PPPP as potential drug reactions to biologics such as adalimumab and infliximab. Large‐scale studies are required to confirm our findings and further explore the pathogenesis for biologic‐associated PPP and PPPP.

01 Jan 2023·Journal of Investigative Dermatology

Comparison of the Inflammatory Circuits in Psoriasis Vulgaris, Non‒Pustular Palmoplantar Psoriasis, and Palmoplantar Pustular Psoriasis

Article

Author: Kalliolias, George D ; Rambhia, Darshna ; Kunjravia, Norma ; Lim, Wei Keat ; Krueger, James G ; Cueto, Inna ; Sleeman, Matthew A ; Hamilton, Jennifer D ; Gonzalez, Juana ; Garcet, Sandra ; Haxhinasto, Sokol ; Bissonnette, Robert ; Freudenberg, Jan ; Harari, Olivier ; Thakker, Paresh ; Wang, Claire Q

Palmoplantar pustular psoriasis (PPPP) and non‒pustular palmoplantar psoriasis (NPPP) are localized, debilitating forms of psoriasis. The inflammatory circuits involved in PPPP and NPPP are not well-understood. To compare the cellular and immunological features that differentiate PPPP and NPPP, skin biopsies were collected from a total of 30 participants with PPPP, NPPP, and psoriasis vulgaris (PV) and from 10 healthy participants. A subset consented to a second biopsy after 3 additional weeks off medication. Histologic staining of lesional and nonlesional skin showed higher neutrophil counts in PPPP than in NPPP and PV and higher CD8⁺ T-cell counts in NPPP. RNA sequencing and transcriptional analysis of skin biopsies showed enhanced IFN-γ pathway activation in NPPP lesions but stronger signatures of IL-17 pathway and neutrophil-related genes (e.g., IL36A) in PPPP lesional skin. Serum analysis on the Olink platform detected higher concentrations of T helper type 1, IFN-γ‒inducible chemokines in NPPP, and higher neutrophil-associated cytokines in PPPP. Taken together, this evidence suggests more pronounced T helper 1‒mediated inflammation in NPPP than in PV and PPPP and stronger neutrophil-associated activity in PPPP than in NPPP and PV. These data support targeting inflammatory pathways associated with neutrophilic inflammation (e.g., IL-36 signaling) for therapeutic development in PPPP.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Porokeratosis Punctata Palmaris Et Plantaris

Basic Info

Related

Analysis